BRIEF-Arch Biopartners' AB569 receives positive opinion from EMA COMP
April 26 (Reuters) - Arch Biopartners Inc
* Arch biopartners' AB569 receives positive opinion from EMA COMP for orphan designation for cystic fibrosis
* Plans to submit an investigational new drug application to FDA for AB569 in second half of 2016
* COMP's positive opinion will be forwarded to EC for final approval of orphan designation, expected to be completed in next few weeks Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.